GLYCOM acquired by ROYAL DSM

EQT completed the acquisition of 100% of Schülke from its parent company, Air Liquide. This transaction represents a strategic carve-out for Air Liquide, allowing the French industrial gas giant to refocus on its core activities while providing Schülke with the independent capital necessary for long-term expansion. Announced during the height of the COVID-19 pandemic, the deal saw increased competition from other major private equity firms (PAI Partners, Ardian) due to Schülke’s critical role in infection prevention

The acquisition of Vision Healthcare NV by Avista Capital Partners marks a significant milestone in the company's strategic journey. The partnership enables Vision to realize further rapid growth and make additional investments that leverage its differentiated direct-to-consumer business model. With Avista's expertise and resources, Vision is well-positioned to expand its geographic reach and accelerate its acquisition strategy into the global direct-to-consumer healthcare market. The transaction also allows Vision to benefit from Avista's experience in the consumer healthcare sector, providing operational guidance and financial resources to drive growth and performance

Warburg Pincus has acquired a 50% co-control stake in Polyplus from ArchiMed, executing a flagship LBO in the European mid-cap space. The transaction structure is characterized by a significant reinvestment from the incumbent sponsor, ArchiMed, ensuring that both private equity firms hold equal equity stakes and voting rights post-closing. To finance this acquisition, a bespoke unitranche debt facility was arranged and provided by Tikehau Capital and Goldman Sachs. The definitive agreement was signed following supreme execution certainty and intense competitive tension prior to the pandemic-induced market slowdown

The divestiture of the Life Sciences division by NN inc. (Paragon Medical) to American Securities represents a pivotal structural transformation for both organizations. For the seller, the transaction provides a necessary capital infusion to significantly reduce corporate debt and reposition its remaining industrial platform toward power and mobile solutions. The strategic rationale for the move centers on the acquirer’s objective to combine the division’s high-precision surgical capabilities with its existing portfolio company, MW Industries, thereby creating a comprehensive engineering powerhouse for specialized fasteners and medical components

LBO France acquired a controlling stake in Dutscher, replacing Five Arrows (who had held the majority since 2014). This Secondary LBO also marked the exit of the founder's son, who held ~40% but had no operational role, completing the transition from a family-owned business to a financial-backed platform.

Ceva Sante Animale completed a historic "Jumbo LBO". This transaction allowed the management team (800+ executives) to retain over 50% of the capital—a record for a deal of this size in France (comparable only to the Legrand buyout in 2002). Four new long-term investors joined the "Friends of Ceva" consortium: Tethys Invest, PSP, Mitsui, and Klocke. Historical investors, led by Temasek, significantly reinvested their proceeds.

The acquisition of the High Ridge Brands Oral Care assets by Perrigo signifies a definitive densification of the group’s specialized hygiene division. The strategic rationale for this transaction hinges on a "category-dominance" maneuver, merging the target’s technical operational depth in the branded-value children’s segment with the acquirer’s massive Ranir platform. This structural alignment provides the organization with the scientific talent and trademark hardware necessary to address the increasing consumer shift toward high-quality, cost-effective oral health solutions

Dentressangle has entered into exclusive negotiations to acquire a majority stake in Marle Group from IK Investment Partners on a preemptive basis, successfully securing the asset outside of a traditional, highly competitive auction process. Marle Group is a premier European leader and a dominant global contract manufacturing organization (CMO) specializing in high-precision orthopedic implants and surgical instruments. The company commands high barriers to entry rooted in its fully vertically integrated manufacturing process (foundry, machining, specialized coating, sterile packaging) and strict international regulatory compliance (FDA, CE mark)

Sterimed, a global leader in medical sterilization packaging, has entered into exclusive negotiations with Sagard to organize a secondary LBO. This transaction facilitates the exit of Meeschaert Capital Partners, which held a majority stake since 2016 following the group's spin-off from ArjoWiggins. The current management team, led by CEO Thibaut Hyvernat, will remain significantly invested in this new chapter.

Permira, the global private equity firm, successfully completed the acquisition of Cambrex Corporation, a premier small molecule CDMO, in a take-private transaction that signaled a major consolidation move in the pharmaceutical services sector. The transaction was structured as a merger whereby shareholders received $60.00 in cash per share, representing a significant premium of 47.1% over the undisturbed share price. The deal allowed Cambrex to delist from the New York Stock Exchange and transition into a private entity, providing the management team with the long-term capital and operational flexibility required to further integrate its acquisitions and invest in global capacity expansion